PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer

BACKGROUND: Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and to establish factors predictive of this resistance. RESUL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kim, Chan, Lee, Choong-Kun, Chon, Hong Jae, Kim, Joo Hoon, Park, Hyung Soon, Heo, Su Jin, Kim, Hyun Jeong, Kim, Tae Soo, Kwon, Woo Sun, Chung, Hyun Cheol, Rha, Sun Young
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768341/
https://ncbi.nlm.nih.gov/pubmed/29371924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados